000288826 001__ 288826
000288826 005__ 20250824022515.0
000288826 0247_ $$2doi$$a10.1016/j.heliyon.2024.e27077
000288826 0247_ $$2pmid$$apmid:38449616
000288826 0247_ $$2pmc$$apmc:PMC10915392
000288826 0247_ $$2altmetric$$aaltmetric:180334550
000288826 037__ $$aDKFZ-2024-00491
000288826 041__ $$aEnglish
000288826 082__ $$a000
000288826 1001_ $$aWang, Yanling$$b0
000288826 245__ $$aThyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer.
000288826 260__ $$aLondon [u.a.]$$bElsevier$$c2024
000288826 3367_ $$2DRIVER$$aarticle
000288826 3367_ $$2DataCite$$aOutput Types/Journal article
000288826 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710164088_7413$$xReview Article
000288826 3367_ $$2BibTeX$$aARTICLE
000288826 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288826 3367_ $$00$$2EndNote$$aJournal Article
000288826 500__ $$a#LA:E055#
000288826 520__ $$aThyroid Dysfunction (TD) is a common immune-related adverse events (irAEs) in the treatment of advanced lung cancer with programmed cell death protein 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors, with incidence accounting for 6-8% of all irAEs. The incidence of TD is receiving increasing attention from clinicians, given its potential impact on clinical efficacy. However, the molecular mechanisms, biomarkers, and clinical impact of TD resulting from PD-1/PD-L1 inhibitor treatment in advanced lung cancer are unclear.To present a comprehensive review of current advancements in research about the molecular mechanisms, influential factors, and clinical manifestations in the treatment of advanced lung cancer with PD-1 and PD-L1 inhibitors, as well as the correlation between TD and the efficacy of PD-1 and PD-L1 inhibitors.A systematic search was conducted using PubMed, Web of Science, Cochrane Library, Embase and Google Scholar databases, with the keywords including thyroid dysfunction, efficacy, mechanisms, immune checkpoint inhibitors, PD-1/PD-L1 inhibitors, and advanced lung cancer.PD-1/PD-L1 inhibitors can induce T cell-mediated destructive thyroiditis, thyroid autoantibody-mediated autoimmunity, and a decrease in the number of immunosuppressive monocytes (circulating cluster of differentiation (CD)14+ human leukocyte antigen (HLA)-DRlow/negatives monocytes, CD14+ HLA-DR + lo/neg), leading to TD. Several factors, including peripheral blood inflammatory markers, body mass index (BMI), baseline thyroid-stimulating hormone (TSH) level, gender, smoking history, hypertension, and previous opioid use, may also contribute to the development of TD. However, there is currently a lack of reliable predictive biomarkers for TD, although anti-thyroid antibodies, TSH levels, and peripheral blood inflammatory markers are expected to be predictive.Interestingly, some studies suggested a positive correlation between TD and clinical efficacy, i.e., patients experiencing TD showed better outcomes in objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS), compared with those without TD. However, most of these studies were single-center and had small sample sizes, so more multi-center studies are needed to provide further data support.TD resulting from PD-1/PD-L1 inhibitor treatment in advanced lung cancer may be associated with good clinical outcomes. The clarification of the molecular mechanisms underlying TD and the identification of reliable predictive biomarkers will guide clinicians in managing TD in this patient population.
000288826 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000288826 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288826 650_7 $$2Other$$aAdvanced lung cancer
000288826 650_7 $$2Other$$aEfficacy
000288826 650_7 $$2Other$$aImmune checkpoint inhibitors
000288826 650_7 $$2Other$$aPD-1/PD-L1 inhibitors
000288826 650_7 $$2Other$$aThyroid dysfunction
000288826 7001_ $$aYang, Xiaoxuan$$b1
000288826 7001_ $$aMa, Jia$$b2
000288826 7001_ $$aChen, Shenglan$$b3
000288826 7001_ $$aGong, Ping$$b4
000288826 7001_ $$0P:(DE-He78)ef14f4d420586757b9d33c826bbe666e$$aDai, Ping$$b5$$eLast author$$udkfz
000288826 773__ $$0PERI:(DE-600)2835763-2$$a10.1016/j.heliyon.2024.e27077$$gVol. 10, no. 5, p. e27077 -$$n5$$pe27077$$tHeliyon$$v10$$x2405-8440$$y2024
000288826 8564_ $$uhttps://inrepo02.dkfz.de/record/288826/files/1-s2.0-S2352396424003773-main-2.pdf
000288826 8564_ $$uhttps://inrepo02.dkfz.de/record/288826/files/1-s2.0-S2352396424003773-main-2.pdf?subformat=pdfa$$xpdfa
000288826 909CO $$ooai:inrepo02.dkfz.de:288826$$pVDB
000288826 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ef14f4d420586757b9d33c826bbe666e$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000288826 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000288826 9141_ $$y2024
000288826 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHELIYON : 2022$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:51:11Z
000288826 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:51:11Z
000288826 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:51:11Z
000288826 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-27
000288826 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-27
000288826 9202_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000288826 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000288826 980__ $$ajournal
000288826 980__ $$aVDB
000288826 980__ $$aI:(DE-He78)E055-20160331
000288826 980__ $$aUNRESTRICTED